Off-Label Recombinant Factor VIIa Use and Thrombosis in Children: A Multi-Center Cohort Study - 02/08/11
, Yuan-Shung Huang, MS c, Kevin Lynch, PhD d, Leslie J. Raffini, MD, MSCE a, Samir S. Shah, MD, MSCE b, c, e
Reprint requests: Dr Char M. Witmer, MD, The Children’s Hospital of Philadelphia, 3501 Civic Center Boulevard, Division of Hematology, CTRB 11th Floor, Philadelphia, PA 19104.Abstract |
Objective |
To describe the off-label use of recombinant factor VIIa (rFVIIa) in tertiary care pediatric hospitals across the United States and to assess thrombotic events.
Study design |
A retrospective multi-center cohort study using the Pediatric Health Information System administrative database. Children 18 years of age or younger who received rFVIIa between 2000 and 2007 were included. A label admission was defined as an admission with an International Classification of Diseases diagnostic code for hemophilia or factor VII deficiency; admissions without these codes were classified as off-label.
Results |
There were 4942 rFVIIa admissions, representing 3764 individual subjects; 74% (3655) of the admissions were off-label. There was a 10-fold increase in the annual rate of off-label admissions from 2000 to 2007 (from 2 to 20.8 per 10 000 hospital admissions, P < .001). The mortality rate in the off-label group was 34% (1258/3655). Thrombotic events occurred in 10.9% (399/3655) of the off-label admissions.
Conclusions |
The off-label use of rFVIIa in hospitalized children is increasing rapidly despite the absence of adequate clinical trials demonstrating safety and efficacy. Thrombotic events are common and mortality is high among patients receiving off-label rFVIIa. Further studies are warranted to determine whether these adverse events are attributable to rFVIIa.
Le texte complet de cet article est disponible en PDF.Mots-clés : CCC, DOS, ICD-9-CM, PHIS, rFVIIa
Plan
| The authors declare no conflicts of interest. |
Vol 158 - N° 5
P. 820 - mai 2011 Retour au numéro
Article précédent
- Exercise Capacity in Pediatric Patients with Inflammatory Bowel Disease
- Hilde E. Ploeger, Tim Takken, Boguslaw Wilk, Robert M. Issenman, Ryan Sears, Soni Suri, Brian W. Timmons
- Cross-Sectional and Longitudinal Assessment of Aortic Root Dilation and Valvular Anomalies in Hypermobile and Classic Ehlers-Danlos Syndrome
- Carrie L. Atzinger, Richard A. Meyer, Philip R. Khoury, Zhiqian Gao, Brad T. Tinkle
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?